Ovarian Cancer: Symptoms, Diagnosis and Treatment

Ovarian cancer is the fifth leading cause of cancer death in women in developed countries and the most lethal gynaecological malignancy. Approximately 315,000 women are diagnosed with ovarian cancer worldwide each year, and over 200,000 die annually. It is called a "silent killer" because it lacks specific early symptoms and is frequently diagnosed at an advanced stage when curative treatment is difficult.

In China, ovarian cancer incidence has been rising — approximately 55,000 new cases annually — partly due to changing reproductive patterns (decreasing parity and breastfeeding are risk factors). The 5-year survival for all stages combined is approximately 40–50%, but for stage I disease caught early it exceeds 90%.

Types of Ovarian Cancer

The ovary contains multiple cell types, giving rise to different tumour types:

Epithelial Ovarian Cancer (EOC)

Accounts for approximately 90% of all ovarian cancers. Arises from the surface epithelium of the ovary or the fallopian tube (increasingly recognised as the dominant site of origin for high-grade serous carcinoma — the most common subtype).

EOC subtypes:

• High-grade serous carcinoma (HGSC) — the most common (~70% of EOC); highly aggressive; arises predominantly from fallopian tube epithelium; strongly associated with BRCA1/2 mutations; typically advanced at diagnosis; platinum-sensitive but frequently recurs
• Clear cell carcinoma (~10%) — often associated with endometriosis; more common in Asian women; relatively platinum-resistant
• Endometrioid carcinoma (~10%) — frequently associated with endometriosis and Lynch syndrome; better prognosis
• Mucinous carcinoma (~3%) — often confined to ovary at diagnosis; often platinum-resistant; must be distinguished from gastrointestinal primary
• Low-grade serous carcinoma — rare; indolent course; lower sensitivity to platinum than HGSC

Non-Epithelial Ovarian Tumours

• Germ cell tumours (dysgerminoma, yolk sac tumour, immature teratoma) — predominantly in young women; highly chemosensitive; often curable
• Sex cord-stromal tumours (granulosa cell tumour, Sertoli-Leydig) — may produce oestrogen or testosterone; often indolent; lower stage at diagnosis

Causes and Risk Factors

BRCA1 and BRCA2 Mutations

The most important genetic risk factor. Women with a BRCA1 mutation have a lifetime ovarian cancer risk of 40–50%; BRCA2 carriers have a 15–25% lifetime risk. BRCA-mutated cancers are predominantly high-grade serous carcinomas and are exquisitely sensitive to platinum chemotherapy and PARP inhibitors.

Testing: BRCA germline testing is recommended for all women diagnosed with high-grade serous ovarian cancer (prevalence of germline BRCA mutation approximately 15–20%) and for their first-degree female relatives. Somatic (tumour) BRCA mutations occur in a further 5–7% of EOC.

Lynch Syndrome

Hereditary mismatch repair deficiency (MLH1, MSH2, MSH6, PMS2 mutations) — increases risk of endometrioid and clear cell ovarian cancer, as well as colorectal, endometrial, and gastric cancer.

Reproductive and Hormonal Factors

• Nulliparity — increased lifetime number of ovulatory cycles correlates with risk
• Early menarche / late menopause — more ovulatory cycles
• Oral contraceptive pill — protective; reduces ovarian cancer risk by approximately 50% with 5+ years of use; protection persists for decades after cessation
• Endometriosis — associated with clear cell and endometrioid subtypes (3–4× increased risk); endometriotic cysts (endometriomas) may undergo malignant transformation
• HRT (particularly oestrogen-only, long-term) — modest association with serous tumours

Other Risk Factors

• Age — most cases diagnosed post-menopausally; median age 63
• Family history — first-degree relative with ovarian cancer, even without BRCA mutation, raises risk
• Talcum powder — perineal use historically associated with modest risk increase; mechanism debated; major lawsuits in the US

Protective factors: oral contraceptive use, pregnancy, breastfeeding, tubal ligation, salpingectomy (risk-reducing bilateral salpingectomy is now recommended at hysterectomy for non-BRCA women; bilateral salpingo-oophorectomy (RRSO) for BRCA1 carriers from age 35–40, BRCA2 carriers from age 40–45).

Symptoms

Ovarian cancer symptoms are non-specific and subtle — which is why most women present with advanced disease.

Common symptoms (often dismissed as IBS or menopausal):

• Persistent abdominal bloating — one of the most common early symptoms; often attributed to diet or IBS
• Pelvic or abdominal pain — persistent, not necessarily severe
• Difficulty eating or early satiety — due to ascites or peritoneal deposits compressing the stomach
• Urinary frequency or urgency — bladder compression
• Change in bowel habit — constipation or looser stool; tumour mass effect
• Unexplained weight loss — in advanced disease
• Fatigue

Advanced disease symptoms:

• Ascites — fluid in the abdomen causing gross abdominal distension; the abdomen may appear tight, shiny, and protuberant
• Pleural effusion — breathlessness from fluid around the lungs
• Palpable abdominal mass

Key clinical message: Any woman with persistent unexplained bloating, pelvic pain, early satiety, or urinary urgency lasting >2–3 weeks should be investigated — particularly if postmenopausal. A 2-week-wait referral pathway for suspected ovarian cancer is standard in many countries.

Diagnosis and Staging

Blood Tests

CA125 (cancer antigen 125) — glycoprotein produced by ovarian epithelial cells; elevated (>35 IU/mL) in approximately 80% of advanced ovarian cancers and in 50% of stage I disease. Not sufficiently sensitive or specific for screening (elevated in endometriosis, fibroids, PID, other cancers, and normal menstruation) but essential for monitoring treatment response and recurrence.

HE4 (human epididymis protein 4) — more specific than CA125 for ovarian cancer; ROMA algorithm (CA125 + HE4 + menopausal status) provides better risk stratification than CA125 alone.

AFP, β-hCG, LDH, inhibin — tumour markers for germ cell and sex cord-stromal tumours in younger women.

Imaging

Pelvic ultrasound — first-line imaging; identifies ovarian masses and characterises features (solid vs cystic; septations; papillary projections; vascularity; ascites). The RMI (Risk of Malignancy Index) — combining CA125, menopausal status, and ultrasound morphology score — guides onward referral.

CT chest/abdomen/pelvis with contrast — the primary staging investigation; identifies peritoneal deposits, omental caking, lymph node involvement, pleural effusions, and liver metastases. Essential for surgical planning.

MRI pelvis — superior soft tissue characterisation; used for complex adnexal masses, uterine disease, and delineating local disease extent.

PET-CT — useful for recurrence staging; detects small nodal deposits missed by CT.

Surgical Staging

Ovarian cancer is ultimately surgically staged — the FIGO staging system is determined at laparotomy or laparoscopy:

Stage	Description	5-Year Survival
I	Confined to ovaries/fallopian tubes	~90%
II	Extends to pelvis	~65–70%
III	Peritoneal spread beyond pelvis / retroperitoneal nodes	25–45%
IV	Distant metastasis (IV A: pleural effusion; IV B: parenchymal, extra-abdominal)	<20%

Approximately 75% of cases are diagnosed at stage III–IV.

Histological Diagnosis

Tissue diagnosis is required — either via:

• Surgical resection (definitive staging + cytoreduction at laparotomy/laparoscopy)
• CT-guided biopsy of an accessible lesion (peritoneal deposit, omental nodule) — for patients with advanced unresectable disease before neoadjuvant chemotherapy

Molecular profiling: BRCA1/BRCA2 (germline + somatic); MMR/MSI; homologous recombination deficiency (HRD) — guides maintenance therapy with PARP inhibitors.

Treatment

Primary Cytoreductive Surgery (Debulking)

For fit patients with advanced ovarian cancer who are surgical candidates — primary debulking surgery (PDS) aims to remove all visible tumour. The degree of residual disease is the most powerful prognostic factor in ovarian cancer: no residual disease (R0 / complete cytoreduction) confers the best survival.

Surgical extent: total hysterectomy + bilateral salpingo-oophorectomy + omentectomy (removal of the omentum, a fat pad often carpeted by tumour) + peritoneal stripping + lymphadenectomy + resection of bowel, bladder, diaphragm, and liver surface deposits as required for complete cytoreduction.

Cytoreductive surgery for advanced ovarian cancer is major pelvic and abdominal surgery, sometimes involving bowel resection and stoma; performed by specialist gynaecological oncologists at high-volume cancer centres.

Interval Debulking Surgery (IDS)

For patients not suitable for primary surgery (medically unfit, or disease distribution making upfront complete resection impossible) — neoadjuvant chemotherapy (NACT) is given first (3 cycles), followed by interval debulking surgery, then further chemotherapy. NACT+IDS achieves comparable overall survival to upfront PDS in patients where complete cytoreduction was not achievable upfront.

Chemotherapy

Standard first-line: platinum-based combination chemotherapy:

• Carboplatin + paclitaxel (every 3 weeks × 6 cycles) — the universal first-line standard
• Weekly dose-dense paclitaxel (ICON8 trial variants) — alternative scheduling; potentially improved tolerability

Most advanced ovarian cancers initially respond well to platinum chemotherapy (80–90% response rate) — but the majority recur. Platinum-sensitive recurrence (relapse >6 months after last platinum) is retreated with platinum-containing regimens. Platinum-resistant recurrence (relapse <6 months) is treated with non-platinum agents.

Bevacizumab (anti-VEGF antibody) — added to chemotherapy and continued as maintenance (ICON7, OCEANS trials): approved for advanced ovarian cancer; improves progression-free survival; particularly beneficial in high-risk stage III–IV and platinum-resistant recurrence; given intravenously every 3 weeks.

PARP Inhibitors — Maintenance Therapy

PARP (poly ADP-ribose polymerase) inhibitors exploit a DNA repair deficiency (homologous recombination deficiency — HRD) present in BRCA-mutated and other HRD-positive ovarian cancers:

• Olaparib (Lynparza) — first PARP inhibitor approved for ovarian cancer; SOLO-1 trial: olaparib maintenance after first-line chemotherapy in BRCA-mutated patients; 3-year PFS 60% vs 27% with placebo; 7-year OS benefit demonstrated; standard of care for BRCA-mutated EOC
• Niraparib (Zejula) — PRIMA trial: benefit in HRD-positive patients (not limited to BRCA); oral once-daily; approved for first-line maintenance and recurrent disease
• Rucaparib (Rubraca) — second-line maintenance for platinum-sensitive recurrent disease

PARP inhibitors are oral tablets — a major advance over chemotherapy infusions; principal side effects: fatigue, nausea, anaemia, myelosuppression, risk of myelodysplastic syndrome (rare, long-term).

Targeted Therapy

Bevacizumab: anti-VEGF antibody; given with chemotherapy and as maintenance; improves PFS in advanced and recurrent disease; side effects: hypertension, proteinuria, wound healing impairment, rare bowel perforation.

Mirvetuximab soravtansine (antibody-drug conjugate targeting folate receptor α): approved for platinum-resistant EOC in high folate receptor α expressors.

Ovarian Cancer Care in China

China's gynaecological oncology centres offer:

• Ovarian cancer assessment: CA125, HE4, ROMA score, pelvic ultrasound, and CT staging; expert multidisciplinary team review
• BRCA and HRD germline and somatic testing: comprehensive molecular profiling; genetic counselling for BRCA-positive families
• Primary cytoreductive surgery: specialist gynaecological oncology surgical teams at major centres; complete cytoreduction (R0) rates comparable to leading international series; bowel, liver, and diaphragm resection capability
• PARP inhibitor access: olaparib, niraparib, and rucaparib — including domestic Chinese PARP inhibitor products (fuzuloparib/pamiparib) approved in China
• Bevacizumab: available with chemotherapy for advanced disease; domestic Chinese bevacizumab biosimilars available
• Cost: care in China is generally less expensive than UK private treatment, but the hospital prices each case individually — ask us for the written quote before you commit.
• Full English care navigation from diagnosis through surgery, chemotherapy, maintenance therapy, and surveillance

Contact a ChinaMedicalTour care navigator to arrange an ovarian cancer assessment, second opinion, or treatment consultation.

---

Medical content based on MSD Manuals and international ovarian cancer guidelines (ESGO, NCCN, NICE). Evidence reviewed 2025.

Frequently Asked Questions

Can foreign patients submit pelvic imaging and gynecology reports for specialist review?

Yes. Pelvic MRI scans, transvaginal ultrasound reports, and histopathology results can be submitted for remote pre-consultation review by experienced Chinese gynecologists.

What surgical and minimally invasive treatments are offered for gynecological conditions in China?

Chinese centers evaluate laparoscopic and hysteroscopic myomectomy, excision of endometriosis, uterine artery embolization, and fertility-preserving surgical interventions.

How is care navigation handled for international gynecological patients?

China Medical Tour provides non-clinical coordination including appointment booking, on-site hospital escort, translation assistance, and certified medical documentation upon completion.